Existing research suggested that mutations in GCM2 could increase the risk of familial or sporadic PHPT (26, 52, 53) and had a tendency for malignancy (26, 53–55), indicating that it might be beneficial for PC and APA patients without CDC73 mutations to screen for GCM2 mutations. Here, GCM2 is linked to pachyonychia congenita.